Lyka Labs Posts Strong Performance in Q1 FY27; Net Profit Rises Over 105% Consolidatedly
Lyka Labs Limited has announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27), reflecting strong performance across both standalone and consolidated operations.The company reported that Standalone Net Total Income increased by 42.67% to Rs. 4272.79 Lacs, while Consolidated Net Total Income rose by 26.95%, also reaching Rs. 4272.79 Lacs.
In terms of revenue growth, Domestic Revenue saw an increase of 15.91% to Rs. 2652.11 Lacs. Export Revenue experienced a significant jump of 68.03%, totaling Rs. 1483.42 Lacs.
Margin analysis showed that the Standalone EBITDA margin stood at 11.84% in Q1 FY27, compared to 14.16% in Q1 FY26. The Consolidated EBITDA margin was reported at 11.74% for Q1 FY27, down from 13.07% in Q1 FY26.
The company’s net profitability improved substantially across the board. Standalone Net Profit increased by 159.06%, reaching Rs. 210.03 Lacs. Consolidated Net Profit saw a growth of 105.44%, amounting to Rs. 204.66 Lacs.
Q1 FY27 Financial Performance Snapshot (Standalone)
The following table details the financial metrics for Lyka Labs Limited in Q1 FY27, comparing them against Q1 FY26 results:| Standalone Q1 FY27 at a glance Particulars | FY27 (Rs. In lacs) | Q1 FY26 (Rs. In lacs) | Growth in % |
|---|---|---|---|
| Revenue from Operations | 4230.94 | 2917.64 | 45.01 |
| EBITDA | 501.14 | 413.06 | 21.32 |
| Other Income | 41.85 | 77.34 | -45.89 |
| Finance Cost | 100.82 | 85.14 | 18.42 |
| Depreciation and amortisation | 200.96 | 211.18 | -4.84 |
| Net Profit after tax | 210.03 | 81.07 | 159.06 |
Consolidated Q1 FY27 Results
The consolidated results for the first quarter ended June 30, 2026, are as follows:| Particulars | Q1 FY27 (Rs. In lacs) | Q1 FY26 (Rs. In lacs) | Growth in % |
|---|---|---|---|
| Revenue from Operations | 4230.94 | 3302.54 | 28.11 |
| EBITDA | 496.57 | 431.73 | 15.02 |
| Other Income | 41.85 | 63.09 | -33.67 |
| Finance Cost | 100.81 | 85.38 | 18.07 |
| Depreciation and amortisation | 200.96 | 211.18 | -4.84 |
| Net Profit after tax | 204.66 | 99.62 | 105.44 |
Revenue Breakdown for Q1 FY27
The revenue streams are segmented into Domestic and Export categories, as detailed below:| Particulars | Q1 FY27 (Rs. In lacs) | Q1 FY26 (Rs. In lacs) | Growth in % |
|---|---|---|---|
| Domestic Sales | 2,652.11 | 2,288.17 | 15.91 |
| Branded Formulation (Domestic) | 737.67 | 454.58 | 62.27 |
| Branded Veterinary (Domestic) | 587.35 | 296.90 | 97.83 |
| P2P (Domestic) | 1,327.09 | 1,536.69 | -13.64 |
| Export Sales | 1,483.42 | 882.85 | 68.03 |
| Branded Formulation (Export) | 1,483.42 | 882.85 | 68.03 |
Lyka Labs Limited specializes in the Manufacturing and Marketing of Finished Formulations for Human and Animal Healthcare across various therapeutic segments.
LYKALABS Stock Price Movement
Shares of the company today slipped by 0.10% to settle at ₹68.07, marking a minor decline in the closing trade. The equity saw trading activity with 7,112 shares recorded throughout the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.